ארצות הברית - אנגלית - NLM (National Library of Medicine)

stat rx usa llc - oxymorphone hydrochloride (unii: 5y2ei94nbc) (oxymorphone - unii:9vxa968e0c) - oxymorphone hydrochloride 5 mg - opana er is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. opana er is not intended for use as a prn analgesic. opana er is not indicated for pain in the immediate post-operative period (12-24 hours following surgery) for patients not previously taking opioids because of the risk of oversedation and respiratory depression requiring reversal with opioid antagonists. opana er is not indicated for pain in the post-operative period if the pain is mild or not expected to persist for an extended period of time. opana er is contraindicated in patients with a known hypersensitivity to oxymorphone hydrochloride or to any of the other ingredients in opana er, or with known hypersensitivity to morphine analogs such as codeine. opana er is not indicated for pain in the immediate post-operative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extende

ארצות הברית - אנגלית - NLM (National Library of Medicine)

stat rx usa llc - oxymorphone hydrochloride (unii: 5y2ei94nbc) (oxymorphone - unii:9vxa968e0c) - oxymorphone hydrochloride 10 mg - opana is indicated for the relief of moderate to severe acute pain where the use of an opioid is appropriate. - opana is contraindicated in patients with a known hypersensitivity to oxymorphone or to any of the other ingredients in opana, or with known hypersensitivity to morphine analogs such as codeine. - opana is contraindicated in patients with respiratory depression, except in monitored settings and in the presence of resuscitative equipment. - opana is contraindicated in patients with acute or severe bronchial asthma or hypercarbia. - opana is contraindicated in any patient who has or is suspected of having paralytic ileus [see warning and precautions (5.8)] . - opana is contraindicated in patients with moderate or severe hepatic impairment [see warnings and precautions (5.6)] . the safety of using oxymorphone in pregnancy has not been established with regard to possible adverse effects on fetal development. the use of opana in pregnancy, in nursing mothers, or in women of child-bearing potential requir

ארצות הברית - אנגלית - NLM (National Library of Medicine)

st marys medical park pharmacy - oxymorphone hydrochloride (unii: 5y2ei94nbc) (oxymorphone - unii:9vxa968e0c) - oxymorphone hydrochloride 20 mg

ארצות הברית - אנגלית - NLM (National Library of Medicine)

lake erie medical & surgical supply dba quality care products llc - oxymorphone hydrochloride (unii: 5y2ei94nbc) (oxymorphone - unii:9vxa968e0c) - oxymorphone hydrochloride 5 mg

ארצות הברית - אנגלית - NLM (National Library of Medicine)

bryant ranch prepack - oxymorphone hydrochloride (unii: 5y2ei94nbc) (oxymorphone - unii:9vxa968e0c) - oxymorphone hydrochloride 40 mg - opana er is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. limitations of usage opana er is not intended for use as an as needed analgesic. opana er is not indicated for pain in the immediate post-operative period if the pain is mild, or not expected to persist for an extended period of time. opana er is only indicated for post-operative use if the patient is already receiving the drug prior to surgery or if the post-operative pain is expected to be moderate or severe and persist for an extended period of time. physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (see american pain society guidelines). opana er is contraindicated in patients who have: - significant respiratory depression - or are suspected of having paralytic ileus - acute or severe bronchial asthma or hypercarbia - moderate and severe hepatic impairment . [s

ארצות הברית - אנגלית - NLM (National Library of Medicine)

bryant ranch prepack - oxymorphone hydrochloride (unii: 5y2ei94nbc) (oxymorphone - unii:9vxa968e0c) - oxymorphone hydrochloride 5 mg

ארצות הברית - אנגלית - NLM (National Library of Medicine)

bryant ranch prepack - oxymorphone hydrochloride (unii: 5y2ei94nbc) (oxymorphone - unii:9vxa968e0c) - oxymorphone hydrochloride 20 mg - enter section text here enter section text here enter section text here 1 indications and usage opana er is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. limitations of usage opana er is not intended for use as an as needed analgesic. opana er is not indicated for pain in the immediate post-operative period if the pain is mild, or not expected to persist for an extended period of time. opana er is only indicated for post-operative use if the patient is already receiving the drug prior to surgery or if the post-operative pain is expected to be moderate or severe and persist for an extended period of time. physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (see american pain society guidelines). 2 dosage and administration 2.1 safe administration instructions opana er tablets are to be swallowed whole and are not to be broken, chewed, dissolved, or crushed.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

precision dose inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 8 mg - hydromorphone hydrochloride tablets, usp are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)] , reserve hydromorphone hydrochloride tablets, usp for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia hydromorphone hydrochloride tablets, usp are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.5)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.5)] - known or suspected gastrointestinal obstruction, including paralytic il

ארצות הברית - אנגלית - NLM (National Library of Medicine)

roxane laboratories, inc. - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride 100 mg in 5 ml - oxycodone hydrochloride oral solution usp, 100 mg per 5 ml (20 mg/ml ) is an opioid analgesic indicated for the management of moderate to severe acute and chronic pain in opioid-tolerant patients. oxycodone hydrochloride oral solution usp, 100 mg per 5 ml (20 mg/ml) may cause fatal respiratory depression when administered to patients not previously exposed to opioids. patients considered to be opioid tolerant are those who are taking at least 30 mg of oral oxycodone per day, or at least 60 mg oral morphine per day, or at least 12 mg hydromorphone per day, or an equianalgesic dose of another opioid, for a week or longer. oxycodone hydrochloride oral solution usp is contraindicated in patients with respiratory depression in the absence of resuscitative equipment. oxycodone hydrochloride oral solution usp is contraindicated in any patient who has or is suspected of having paralytic ileus. oxycodone hydrochloride oral solution usp is contraindicated in patients with acute or severe bronchial asthma or hypercarbi

ארצות הברית - אנגלית - NLM (National Library of Medicine)

actavis pharma, inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 8 mg - hydromorphone hydrochloride extended-release tablets are indicated for the management of pain in o p i o i d - t o l e r a n t  patients severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. patients considered opioid tolerant are those who are receiving, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. l i m i tat i o ns   of   u s e - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve hydromorphone hydrochloride extended-release tablets for use in patients for whom  alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are inef